TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Purchases $79,650.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Sean Murphy bought 15,000 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were acquired at an average cost of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the transaction, the insider now owns 182,732 shares of the company’s stock, valued at approximately $970,306.92. The trade was a 8.94 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

TriSalus Life Sciences Stock Performance

NASDAQ TLSI opened at $5.11 on Friday. The firm has a market capitalization of $155.82 million, a PE ratio of -2.05 and a beta of 0.51. TriSalus Life Sciences, Inc. has a one year low of $3.50 and a one year high of $10.42. The company has a 50-day simple moving average of $4.59 and a 200-day simple moving average of $4.75.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in shares of TriSalus Life Sciences in the 3rd quarter worth approximately $92,000. Geode Capital Management LLC increased its position in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the period. Vestcor Inc bought a new stake in TriSalus Life Sciences in the third quarter valued at $108,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the third quarter valued at $184,000. Finally, Walleye Capital LLC bought a new position in shares of TriSalus Life Sciences during the third quarter worth about $66,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TLSI shares. Canaccord Genuity Group lowered their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Northland Securities started coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Roth Mkm reissued a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Finally, Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.